Brokerage : Daishin Securities
Analyst : Kahye Hong, Cherry Lee
Investment Rating : BUY (Initiation)
Target Price : KRW 280,000 (Initiation)
Core Momentum : Structural EBITDA margin expansion into the upper-30% range following merger channel inventory resolution, backed by portfolio leverage and new CMO contracts
📊 1. [Valuation & Key Financial Metrics]
- Rating and Target Price: BUY (Initiation), 6-Month Target Price KRW 280,000 (Initiation, calculated by applying a Target Multiple of 28.0x—a premium vs global peers—to 12mF EBITDA of KRW 2,258.9B, reflecting in-house production, direct sales channels, and CMO diversification), offering 52.8% upside from the base share price of KRW 182,500 (as of 26.05.19).
- Global Peer Valuation Comparison:
- Celltrion: Market Cap USD 27.165B, 12M Fwd P/E 28.4x, EPS 2-yr CAGR 39%, EBITDA margin (’26E) 39.1%, 12M Fwd EV/EBITDA 20.4x, EBITDA 2-yr CAGR 27%
- Samsung Epis Holdings: Market Cap USD 8.251B, 12M Fwd P/E 29.9x, EBITDA margin (’26E) 25.7%, 12M Fwd EV/EBITDA 26.8x
- Sandoz: Market Cap USD 36.755B, 12M Fwd P/E 20.6x, EPS 2-yr CAGR 17%, EBITDA margin (’26E) 22.6%, 12M Fwd EV/EBITDA 14.9x, EBITDA 2-yr CAGR 13%
- Consolidated Financial Summary & Forecasts:
- 2024A: Revenue KRW 3,557B, Operating Profit KRW 492B, Net Profit (Controlling) KRW 423B, EPS KRW 1,787, P/E 101.1x, P/B 2.4x, ROE 2.5%
- 2025A: Revenue KRW 4,162B, Operating Profit KRW 1,168B (OPM 28.1%), Net Profit (Controlling) KRW 1,030B, EPS KRW 4,447, P/E 40.7x, P/B 2.4x, ROE 5.9%
- 2026F: Revenue KRW 5,220B (+25.4% YoY), Operating Profit KRW 1,743B (+49.1% YoY, OPM 33.4%), Net Profit (Controlling) KRW 1,292B, EPS KRW 5,772, P/E 32.7x, P/B 2.3x, ROE 7.3%
- 2027F: Revenue KRW 6,962B (+33.4% YoY), Operating Profit KRW 2,519B (+44.6% YoY, OPM 36.2%), Net Profit (Controlling) KRW 1,874B, EPS KRW 8,463, P/E 22.3x, P/B 2.1x, ROE 9.9%
- 2028F: Revenue KRW 7,459B, Operating Profit KRW 2,834B (OPM 38.0%), Net Profit (Controlling) KRW 2,109B, EPS KRW 9,525, P/E 19.8x, P/B 1.9x, ROE 10.2%
🚀 2. [Market Opportunities & Business Outlook]
- Structural Margin Recovery via Vertical Integration:
- Resolution of post-merger channel inventory issues provides visibility on structural profitability driven by internal manufacturing and direct global distribution, supporting EBITDA margins in the high-30% range.
- OPM is projected to recover to ~33% in 2026 as product mix enhancements accelerate.
- Portfolio Expansion & Fixed-Cost Leverage:
- The commercial product portfolio is targeted to scale from 11 products currently to 18 by 2030 and 41 by 2038.
- Progressive additions to the commercial lineup are expected to reinforce operating leverage through fixed-cost absorption.
- CMO Revenue Visibility from Global Pharma:
- Secured over KRW 970B in cumulative production orders through 2029 from global pharmaceutical clients, including Eli Lilly.
- Stable revenue contributions are projected starting in 2027 via portfolio diversification, while US capacity expansions address potential tariff exposures.
- Novel Pipeline Catalysts: Readouts from Phase 1 clinical trials of CT-P70 and CT-P71 expected in 1Q27 represent potential upside catalysts for corporate valuation.
📝 Editor’s Comment (Perspective)
The analyst views Celltrion as a vertically integrated biopharmaceutical company entering a phase of structural margin recovery—with EBITDA margins advancing toward the upper-30% range—as merger-related channel inventory issues dissipate and internal production and sales networks mature. This perspective places strategic importance on fixed-cost absorption from long-term portfolio additions and revenue diversification through global CMO contracts rather than near-term volatility.
To determine whether this investment thesis continues to materialize, key tracking points will be whether operating margins sustain a recovery trajectory toward the 30% range in subsequent quarters, whether CMO production agreements convert into reported revenue starting in 2027 as projected, and whether Phase 1 clinical data for CT-P70 and CT-P71 are delivered in 1Q27. These developments can be verified through upcoming quarterly earnings releases, official IR presentations, and periodic disclosures.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)